RENNIE ORANGE

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

CALCIUM CARBONATE; MAGNESIUM CARBONATE

Dostępny od:

BAYER ISRAEL LTD

Kod ATC:

A02AC10

Forma farmaceutyczna:

CHEWABLE TABLETS

Skład:

CALCIUM CARBONATE 680 MG; MAGNESIUM CARBONATE 80 MG

Droga podania:

PER OS

Typ recepty:

Not required

Wyprodukowano przez:

DELPHARM GAILLARD, FRANCE

Grupa terapeutyczna:

COMBINATIONS

Dziedzina terapeutyczna:

COMBINATIONS

Wskazania:

Relief of hyperacidity and heartburn.

Data autoryzacji:

2015-07-31

Ulotka dla pacjenta

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed without a doctor's prescription
RENNIE
® ORANGE
CHEWABLE TABLETS
ACTIVE INGREDIENTS:
Every chewable tablet contains:
Calcium carbonate 680 mg (equivalent to 272 mg calcium)
Magnesium carbonate (heavy) 80 mg
INACTIVE INGREDIENTS AND ALLERGENS: see section 2 under "Important
information about some of
this medicine’s ingredients" and section 6 "Additional information".
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains
concise information about this medicine. If you have any further
questions, consult your doctor or
pharmacist.
Take the medicine according to the instructions in the section about
dose in this leaflet. Consult
your pharmacist if you need further information. Contact a doctor if
your symptoms of illness get
worse or do not improve after 14 days.
1.
WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the relief of gastric hyperacidity and
heartburn.
THERAPEUTIC GROUP: antacid.
Rennie is used for treatment of symptoms resulting from reflux of
acidic gastric content to the
oesophagus and mouth, causing a sensation of burning or pain behind
the sternum.
Rennie is also used for treatment of symptoms caused by hyperacidity
of gastric content, e.g. in
case of heartburn. Rennie can also be used for the treatment of
symptoms caused by an ulcer in
the upper digestive tract.
2.
BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
•
you are sensitive (allergic) to calcium carbonate or to magnesium
carbonate or to any of the
additional ingredients contained in the medicine (for the list of the
inactive ingredients, see
section 6
"Additional information").
•
you suffer from a severe kidney dysfunction or kidney stones.
•
you suffer from high calcium levels or low phosphate levels in the
blood.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
BEFORE STARTING TREATMENT WITH THE MEDICINE, TELL YOUR DOCTOR IF:
•
you suffer from sarcoidosis (an infl

Charakterystyka produktu

1. NAME OF THE MEDICINAL PRODUCT
Rennie Orange
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains 680 mg calcium carbonate, equivalent to
272.3 mg calcium
and 80 mg magnesium carbonate, equivalent to 23.1 mg magnesium.
Excipients with known effect: each chewable tablet contains 475 mg
sucrose.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets.
Rennie is a creamy-white coloured, square tablet with rounded edges
inscribed with
“RENNIE” on both sides; the tablet has an orange flavour.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Relief of hyperacidity and heartburn.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
For adults and children over the age of 12 years:
1 -2 tablets are to be sucked or chewed, as needed, preferably circa 1
hour after food and
before going to bed.
For the treatment of heartburn, an additional 1 -2 tablets may be
taken between those
times.
Do not take more than 10 tablets per day. The patient must be advised
to consult a doctor
if the symptoms persist for longer than 14 days.
It is advisable to wait roughly 1 -2 hours between taking other
medicines and taking
Rennie.
Paediatric patients:
This medicine is not to be taken by children under the age of 12
years. The safety and
efficacy in children aged under 12 years have not yet been
established.
Method of administration:
For oral use. To be chewed or sucked. The tablets can be taken without
water.
As with all antacids, in the event of persistent symptoms, diagnostic
measures are
recommended to exclude serious diseases.
For special warnings and precautions during use: see section 4.4.
4.3 CONTRAINDICATIONS
-
Hypersensitivity to the active substances or to any of the excipients
listed in
section 6.1.
-
Severe renal insufficiency, hypercalcaemia and/or conditions resulting
in
hypercalcaemia.
-
Pre-existing hypophosphataemia.
-
Nephrolithiasis due to calcium-containing stones.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use should be avoided.
If symptoms persist